News

Neurocrine Biosciences: Still A Buy After 30% Uplift Since My Last Coverage
Neurocrine Biosciences' potential shines with robust assets, strong pipeline, and growth opportunities. Learn more about NBIX ...
Enid News & Eagle15d
Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company ... - enidnews.com
Proposed reverse merger with OrthoCellix, a wholly-owned subsidiary of Ocugen, to create Nasdaq-listed, late clinical-stage regenerative cell therapy company with a first-in-class technology ...
The Bakersfield Californian15d
Candel Therapeutics Appoints Charles Schoch as Chief Financial Officer
NEEDHAM, Mass., June 23, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal ...
Business Wire18d
Candid Therapeutics Advances Portfolio of Novel T-Cell Engagers into Five Autoimmune Diseases for Clinical Evaluation - Business Wire
SAN DIEGO--(BUSINESS WIRE)--Candid Therapeutics, Inc. (“Candid”), a clinical-stage biotechnology company redefining the treatment of autoimmune and inflammatory diseases through novel T-cell ...
Business Wire20d
Coya Therapeutics to Present at the iAccess Alpha Virtual Best Ideas Summer Conference on June 24 – 25, 2025 - Business Wire
Investor Contact David Snyder, CFO [email protected] CORE IR Bret Shapiro [email protected] 561-479-8566 Media Contacts For Coya Therapeutics: Kati Waldenburg [email protected] ...
Morningstar20d
Draig Therapeutics Launches with $140 Million (£107 Million) Total Investment to Advance its Portfolio of Next-Generation Therapies for Major Neuropsychiatric ... - Morningstar
Home News GlobeNewswire Draig Therapeutics Launches with $140 Million (£107 Million) Total Investment to Advance its Portfolio of Next-Generation Therapies for Major Neuropsychiatric Disorders ...
Seeking Alpha20d
Eli Lilly to acquire Verve Therapeutics for up to $1.3B
Eli Lilly (LLY) is reportedly nearing a deal to acquire gene editing startup Verve Therapeutics (VERV) for up to $1.3 billion, the Financial Times reported.
The Bakersfield Californian21d
Ashvattha Therapeutics to Present Data on Novel Nanomedicine Radiotracers at SNMMI Annual Meeting - bakersfield.com
REDWOOD CITY, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue ...
The Daily News21d
Arialys Therapeutics Publishes Preclinical Data in Nature Communications Supporting ART5803 as a First-in-Class Precision Therapeutic for Anti-NMDA Receptor Autoimmune ...
Arialys Therapeutics, a clinical-stage biotechnology company pioneering new precision medicines for autoimmune neuropsychiatric diseases, today announced the publication of preclinical data in Nature ...
Morningstar25d
Grace Therapeutics to Participate in the 2025 BIO International Conference - Morningstar
Grace Therapeutics Contact: Prashant Kohli Chief Executive Officer Tel: 450-686-4555 Email: [email protected] www.gracetx.com Investor Relations: LifeSci Advisors Mike Moyer Managing Director Phone ...